psychopharmacology(redirected from Neuropsychopharmacology)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Antimanic and Hallucinogenic Drugs
A discipline that merges the subject matter of psychology, which studies cognition, emotion, and behavior, and pharmacology, which characterizes different drugs. Thus, psychopharmacology focuses on characterizing drugs that affect thinking, feeling, and action. In addition, psychopharmacology places particular emphasis on those drugs that affect abnormalities in thought, affect, and behavior, and thus has a relationship to psychiatry. Psychopharmacology is predominantly, but not exclusively, concerned with four major classes of drugs that are of clinical significance in controlling four major categories of psychiatric disorder: anxiety, depression, mania, and schizophrenia.
Anxiety is an emotional state that can range in intensity from mild apprehension and nervousness to intense fear and even terror. It has been estimated that 2–4% of the general population suffer from an anxiety disorder at some time. Although anxiety in some form is a common experience, it can become so intense and pervasive as to be debilitating; it may therefore require psychiatric attention and treatment with an anxiolytic drug. There are three major groups of anxiolytics. Members of the first group are called propanediols; meprobamate is the most widely used. The second group is the barbiturates, of which phenobarbital is the most generally prescribed. The third group, most frequently prescribed, is the benzodiazepines, the best known of which is diazepam.
A major advance in understanding the benzodiazepines was the identification of the cellular sites at which these drugs act (so-called benzodiazepine receptors). The distribution of these receptors in the brain has also been found to have a striking parallel to the distribution of the receptors for a naturally occurring substance called gamma-amino butyric acid (GABA). Furthermore, it is known that GABA has a ubiquitous inhibitory role in modulating brain function. Most importantly, it is now clear that benzodiazepines share a biochemical property in that all augment the activity of GABA. See Anxiety disorders, Serotonin
The symptoms of depression can include a sense of sadness, hopelessness, despair, and irritability, as well as suicidal thoughts and attempts, which are sometimes successful. In addition, physical symptoms such as loss of appetite, sleep disturbances, and psychomotor agitation are often associated with depression. When depression becomes so pervasive and intense that normal functioning is impaired, antidepressant medication may be indicated. It has been estimated that as much as 6% of the population will require antidepressant medication at some time in their lives.
There are two major groups of antidepressant drugs. Members of the first group are called heterocyclics because of their characteristic chemical structures. Members of the second group, which are less often prescribed, are called monoamine oxidase inhibitors. See Monoamine oxidase
The antidepressants typically require at least several weeks of chronic administration before they become effective in alleviating depression. This contrasts with the anxiolytics, which are effective in reducing anxiety in hours and even minutes. Another difference between these two classes of drugs is that the anxiolytics are more likely to be efficacious: anxiolytics are effective in the vast majority of nonphobic, anxious patients, whereas the antidepressants are effective in only about 65–70% of depressed patients. See Affective disorders
Manic episodes are characterized by hyperactivity, grandiosity, flight of ideas, and belligerence; affected patients appear to be euphoric, have racing thoughts, delusions of grandeur, and poor if not self-destructive judgment. Periods of depression follow these episodes of mania in the majority of patients. The cycles of this bipolar disorder are typically interspersed among periods of normality that are, in most cases, relatively protracted.
Mania can usually be managed by chronic treatment with lithium salts and can be expected to be effective in 70–80% of the individuals treated. Furthermore, the period of depression that typically follows the manic episode can usually be prevented, or at least attenuated, if lithium treatment is maintained after the manic phase has subsided. Any periods of depression that do occur can be managed by antidepressant drugs. Lithium is no longer the only drug used in the management of mania. Carbamazepine, an anticonvulsant that is used in the treatment of epilepsy, is also useful in the treatment of periods of mania.
Schizophrenia is a form of psychosis; it incorporates a broad range of symptoms that can include bizarre delusions, hallucinations, incoherence of thought processes, inappropriate affect, and grossly disorganized movements. It affects 1–2% of the population. The symptoms of schizophrenia can be controlled, in varying degrees, by a large group of drugs called antipsychotics. Symptom management requires chronic medication and can be expected in about 80% or more of the schizophrenics treated. However, management is only partially successful in that normal functioning is not completely restored in most patients.
The antipsychotics have a broad range of side effects among which are disturbances of movement that fall into two general classes. The first class includes an array of symptoms very like those characteristic of Parkinson's disease. The second class of movement disorder is called tardive dyskinesia. Signs of this disturbance typically include involuntary movements that most often affect the tongue and facial and neck muscles but can also include the digits and trunk.
Although different antipsychotic drugs have different kinds and degrees of side effects, all share a single biochemical action: they all attenuate the activity of dopamine, a naturally occurring substance in the brain. The reduction in dopamine activity produced by the antipsychotics directly accounts for their effects on motor behavior. It is to be expected, therefore, that disrupted dopamine activity in this system would produce disturbances of movement. It is less clear, however, whether reduced dopamine function is also a factor in the process by which these drugs control psychotic (including schizophrenic) symptoms. See Schizophrenia
a multifaceted branch of theoretical and clinical medicine that develops psychotropic agents and studies their mechanisms of action and clinical efficacy. Theoretical psychopharmacology is based on and uses the methods of pharmacology, biochemistry, neurophysiology, and other disciplines. Modern psychopharmacology is divided into psychopharmacokinetics, psychopharmacogenetics, and a number of other areas. It is of particular importance to psychiatry; psychopharmacotherapy is a special field developing within psychiatry to study the use of drugs in the treatment of mental disorders.
The term “psychopharmacology” was introduced by the German scientist D. Macht in 1920. Psychopharmacology as a science dates to 1952, when the French pharmacologist S. Courvoisier and the French surgeon H. M. Laborit studied Aminazinum, a phenothiazine derivative of chlorpromazine, capable of inducing an unusual state of tranquility without disturbing the mind in the way that narcotics do; that same year the French psychiatrists J. Delay, P. Deniker, and J. Harl used the drug to treat psychoses.
Because of its simplicity and safety, psychopharmacotherapy has become a routine mode of therapy for mental patients both in and out of hospitals. The combination of extended psychotherapy and social and work rehabilitation has enabled many patients who had spent much of their lives in mental hospitals to return to their families and resume work. Psychopharmacology has also altered the clinical picture of many psychoses, making their course more favorable (drug-induced pathomorphism). The use of psychopharmacological methods to study the symptomatology and course of psychoses has led to the development of a new branch of medicine, pharmacopsychiatry.
The characteristics of clinical psychopharmacology in the USSR are determined by the dispensary system, which makes it possible to study the effect of psychotropic agents on the course of psychoses both in the hospital when the psychosis is acute and under outpatient conditions; in other words, it allows study of the influence of psychotropic agents on the entire course of a disease and on the body as a whole. Although it does not act on the causes of diseases, psychopharmacotherapy significantly affects their pathogenesis, clinical symptoms, and course.
REFERENCESTemkov, I., and K. Kirov. Klinicheskaia psikhofarmakologiia. Moscow, 1971. (Translated from Bulgarian.)
Avrutskii, G. Ia., I. Ia. Gurovich, and V. V. Gromova, Farmakoterapiia psikhicheskikh zabolevanii. Moscow, 1974.
Laborit, H., P. Huguenard, and R. Alluaume. “Un Nouveau Stabilisateur végétatif (Le 4560 RP).” Presse médicale, 1952, vol. 60, no. 10, pp. 206–08.
Delay, J., P. Deniker, and J. Harl. “Utilisation en thérapeutique, psychiatrique d’une phénothiazine d’action centrale élective (4560 RP).” Annales médicopsychologiques, 1952, vol. 110(2), pp. 112–17.
Biological Treatment of Mental Illness. Edited by M. Rinkel, New York .
G. IA. AVRUTSKII